Aragen, a globally renowned Contract Research, Development and Manufacturing Organization (CRDMO), has secured $100 million in investment from Quadria Capital, an Asia healthcare-focused Private Equity fund. With this investment, Quadria joins Goldman Sachs as the second strategic investor in Aragen.
The investment will result in Quadria acquiring a minority stake in Aragen, at an approximate valuation of $1.4 billion, primarily through a fresh capital infusion, with a small portion from the sale of shares by existing investors.
The funds will be used to expand its capabilities and infrastructure, enabling the company to meet the growing demand for outsourcing services from innovators in the US and Europe.
“We are delighted to welcome Quadria to Aragen. This investment marks a pivotal moment as we scale to meet the needs of a rapidly evolving market. Our expanded capabilities will allow us to support the rising demand for integrated discovery and manufacturing services, and, most importantly, help our customers accelerate their programs to market faster and more efficiently,” said Manni Kantipudi, CEO, Aragen Life Science.
Amit Varma, Managing Partner and co-Founder of Quadria Capital, said, “The pharmaceutical outsourcing sector presents compelling growth opportunities, especially in the current environment which is driven by global supply chain reorganization. Aragen’s impressive track record, customer-centric approach, and commitment to innovation make it an ideal partner for global pharmaceutical companies. We look forward to partnering with them and supporting their next phase of growth.”
Aragen Life Sciences (formerly GVK Biosciences), established in 2001 by G V Sanjay Reddy, is a globally renowned R&D and manufacturing solutions provider to the global life sciences industries. It offers a range of solutions across the drug discovery, development and manufacturing continuum to advance small and large-molecule programs.
Arage operates through a global network of eight sites with a team of ~4500 employees and 450+ PhDs. Arage has seen it grow its global clientele to 400+ clients, including 15 of the top 20 large pharma.
